Easywell Biomedicals (ROCO:1799) Other Financing: NT$-186.9 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:1799 Easywell Biomedicals Inc ROCO:1799
55 GF Score
Price NT$32.25
GF Value NT$75.40
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Easywell Biomedicals Other Financing?

Easywell Biomedicals ROCO:1799 -5.43% 55 Other Financing is NT$-186.9 Mil as of Dec. 2025. GuruFocus rates ROCO:1799 with a GF Score™ of 55/100 and a GF Value™ of NT$75.40 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Easywell Biomedicals's Other Financing for the three months ended in Dec. 2025 was NT$23.0 Mil.

Easywell Biomedicals's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-186.9 Mil.

Easywell Biomedicals Other Financing Historical Data

* Premium members only.

The historical data trend for Easywell Biomedicals's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Easywell Biomedicals Other Financing Chart

Easywell Biomedicals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 134.39 -49.89 -186.89

Easywell Biomedicals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.32 -191.52 -19.14 0.81 22.96
ROCO:1799
55GF Score
Easywell Biomedicals Inc ROCO:1799
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Easywell Biomedicals Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-186.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of NT$-186.9 Mil mean?
Easywell Biomedicals (ROCO:1799) has a Other Financing of NT$-186.9 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Easywell Biomedicals and its competitors.
Is Easywell Biomedicals' Other Financing too high?
Easywell Biomedicals' current Other Financing is NT$-186.9 Mil. Overall, Easywell Biomedicals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Easywell Biomedicals' Other Financing compare to ZTS and UTHR?
Easywell Biomedicals' Other Financing of NT$-186.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Easywell Biomedicals and its competitors. Easywell Biomedicals's current Other Financing is NT$-186.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Easywell Biomedicals stock overvalued right now?
Based on GuruFocus' analysis, Easywell Biomedicals (ROCO:1799) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$75.40, compared to a current price of NT$32.25 — trading 57.2% below its estimated fair value. The current Other Financing is NT$-186.9 Mil. Easywell Biomedicals' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Easywell Biomedicals (ROCO:1799), the current Other Financing is NT$-186.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Easywell Biomedicals (ROCO:1799) Overvalued in 2026?

Based on GuruFocus' analysis, Easywell Biomedicals stock appears to be undervalued. The current stock price of NT$32.25 is trading 57.2% below its estimated GF Value™ of NT$75.40. GuruFocus considers Easywell Biomedicals to be Significantly Undervalued.

Key valuation signals for ROCO:1799:

  • Other Financing: NT$-186.9 Mil
  • GF Value™: NT$75.40 vs. price of NT$32.25 (57.2% below fair value)
  • GF Score™: 55/100 with 3 warning signs

No single metric tells the full story. See the ROCO:1799 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Easywell Biomedicals Business Description

Address No.10, Yanfa 2nd Road, Hsinchu Science Park, 1st floor, Hsinchu, TWN, 30076
Easywell Biomedicals Inc is engaged in drug development, manufacturing, and sales of active pharmaceutical ingredients, generic drugs, and new drugs. It focuses on complex generics, new drug delivery platforms, and regenerative medicines, with cGMP. The company's segments include the Drug Development segment and the Other segment. Geographically, the company operates in America, China, and Taiwan regions.
55GF Score

Get the complete analysis for ROCO:1799

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.25
Price
NT$75.40
GF Value